Zhitong Finance App News, Prodrug (000739.SZ) issued an announcement. Recently, Zhejiang Projutai Pharmaceutical Co., Ltd. (“Jutai Pharmaceutical”), a wholly-owned subsidiary of the company, received a notice from the US Food and Drug Administration (“US FDA”). Jutai Pharmaceutical's simplified new drug application (ANDA, or US generic drug application) declared to the US FDA has been approved.

Brixetam tablets are a novel anti-seizure drug. It is a derivative of the second-generation anticonvulsant levetiracetam. It is mainly used to treat partial seizures and related types of epilepsy. According to relevant data, the sales volume of brinacetam tablets in the US market in 2025 is about US$823 million.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.